Malaria Vaccine Candidates

MSP3/LSP

GMP development of below 96 mer peptide for Clinical Phase II monitored in Africa

PfPEBS

GMP development of below 131 mer peptide for Clinical Phase I monitored in Switzerland

LSA3

Preclinical development